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Background: Paroxysmal hemicrania (PH) is a probably underreported primary headache disorder. It is
characterized by repeated attacks of severe, strictly unilateral pain lasting 2 to 30 minutes localized to orbital,
supraorbital, and temporal areas accompanied by ipsilateral autonomic features. The hallmark of PH is the absolute
cessation of the headache with indomethacin. However, these all features may not be present in all cases and a
few cases may remain unclassified according to the 2nd Edition of The International classification of Headache
Disorders (ICHD-II) criteria for PH.
Methods: Twenty-two patients were included in this retrospective observation.
Results: We describe 17 patients, observed over six years, who fulfilled the ICHD-II criteria for PH. In parallel, we
identified five more patients in whom one of the features of the diagnostic criteria for PH was missing. Two
patients did not show any evidence of cranial autonomic feature during the attacks of headache. Another two
patients did not fulfill the criteria for PH as the maximum attack frequency was less than five. One patient had an
incomplete response to indomethacin.
Conclusion: A subset of patients may not have all the defined features of PH and there is a need for refinement of
the existing diagnostic criteria.
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Paroxysmal hemicrania (PH) is a rare primary headache
disorder. It is classified in group 3 of the 2nd Edition
of The International classification of Headache Disor-
ders (ICHD-II) along with other trigeminal autonomic
cephalalgias (TACs). The characteristic features of PH
are: (a) repeated attacks of severe unilateral, orbital, supra-
orbital or temporal pain lasting for 2–30 min; (b) at least
one ipsilateral cranial autonomic feature; (c) attacks fre-
quency > 5 per day for more than half of the time,
(d) complete response to therapeutic doses of indometh-
acin. All four characteristic features are essential to satisfy
the ICHD-II criteria for PH [1]. However, a few patients
may have atypical presentation [2,3].* Correspondence: drprakashs@yahoo.co.in
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in any medium, provided the original work is pHerein, in a retrospective study, we report 17 patients
who fulfilled the ICHD-II criteria for PH. In parallel, we
identified a group of patients (5 patients) who met all
criteria minus one (either absence of cranial autonomic
features or headache frequency < 5 per day or complete
response to indomethacin).Methods
We performed a retrospective chart review of all patients
with a putative diagnosis of PH, seen in the neurology de-
partment at our institute from February 2006 to July 2012.
The patients having a diagnosis of PH or PH like headache
and with a minimum follow-up of 3 months duration were
included in the study. We reviewed the charts of each in-
dividual. A few patients were interviewed by telephone to
complete the follow-up. Exclusion criteria were: (a) a pos-
sible secondary PH; (b) patients who were never subjected
for neuroimaging, as we did not rule out the possibility ofan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Epidemiological and clinical features of patients
with parosysmal hemicrania
Parameters (n-17)
Age ( years)(mean, range) 38 ± 12.3, 21–60
Sex (M:F) 1:1.1 ( 8:9)
Duration of illness
Mean (SD) 38.2 ± 38.1 months













Infra- orbital /maxillary 4 (24)




Non throbbing 12 (71)
Both throbbing and non throbbing 4 (24)





Restlessness / agitation 13 (76)
Autonomic symptoms, n (%)
Tearing 13 (76)
Conjunctival injection 11 (65)
Feeling of sand / itching in eye 8 ( 47)
Nasal stuffiness 7 (41)
Rhinorrhea 7 (41)
Ptosis 5 (29)
Lid edema 3 (18)
Miosis 1 (06)
Migrainous symptoms, n (%)
At least one migrainous symptom 9 (53)
Nausea 5 (29)
Vomiting 1 (6)
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months duration. The study did not require approval by
the local ethics committee as per the local regulations for
retrospective observation. The majority of patients were
seen and examined by a neurologist (SP). The patients
fulfilling the ICHD-II criteria for PH were tabulated.
Data are presented as percentages or as arithmetic
mean with SD. Student’s t-test was used to compare the
continuous data between the subgroups. The chi-square
test with Yates’s correction was used for categorical
data. A p-value < 0.05 was defined as statistically signi-
ficant. Patients with atypical features were tabulated
separately.
Results
A total of 28 patients were identified with a putative diag-
nosis of PH or PH-like headache. One patient was ex-
cluded because of the possibility of secondary PH (pituitary
adenoma). One patient was never subjected to neuroimag-
ing and was excluded from the final analyses. Two other
patients were excluded because of the incomplete follow-
up (< 3 months). Two patients were excluded because of
the incomplete data entry. Finally, twenty-two patients
were identified. Seventeen patients (77%) fulfilled the
ICHD-II criteria for PH. Two patients (9%) did not show
any evidence of cranial autonomic features. Two patients
(9%) did not fulfill the criteria for PH as the maximum at-
tack frequency was less than five. One patient (5%) did not
show a complete response to indomethacin.
Epidemiological profiles, and clinical features of
patients fulfilling the criteria for PH (17 patients) are
noted in Table 1. Patients with atypical features (with
no cranial autonomic features or headache frequency
< 5 per day or incomplete response to indomethacin)
were summarized separately in Table 2.
Epidemiological and clinical features of patients fulfilling
the ICHD-II criteria for PH
The mean age of participants was 38 years, 53% were
female. The mean illness duration was 38.2 ± 38.1 months.
All patients had strictly unilateral pain. None of the
patients reported bilateral or side-shifting pain. All
patients reported pain in the distribution defined in
the ICHD-II diagnostic criteria for PH. Orbital/retro
orbital was the most common site of pain (88%).
Temporal and frontal regions were two other com-
mon sites of pain. Two patients (12%) reported pain
even in the neck. All patients had at least one auto-
nomic feature as defined in the diagnostic criteria for
PH. However, autonomic features were not consistent
in each attack in every patient. Only six patients
(35%) reported autonomic features in each or most of
the attacks. In five patients (29%), cranial autonomic
features were noted in less than half of the attacks.
Table 1 Epidemiological and clinical features of patients






Restless Leg Syndrome 1(6)
Follow up duration (months)
(mean,SD, range) 12.5 ± 6.7, 3–24
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were the two most common cranial autonomic fea-
tures. Other common cranial autonomic features
were feeling of sand/itching in the eye (47%), nasal
stuffiness (41%), rhinorrhea (41%), and ptosis (29%).
Most patients (88%) reported their pain as severe or very
severe. Only two patients (12%) reported their pain as
moderately severe. Seventy-six percent patients used the
word “excruciating” to define their pains. Fifty-three per-
cent patients reported their pain as throbbing. Interictal
pain was noted in eight (47%) patients. The ipsilateral




Duration of illness (months) 9 14
Course Chronic Ch
Laterality Right Lef
Site of pain Orb, tem, Orb
Character of pain Severe, throb, nonthrob Sev
Interictal pain Yes –
Autonomic features – –
Migrainous features nau, phot, na
Restlessness yes yes
Nocturnal attacks yes yes
Frequency of attacks ( range /day) 4–10 4–
Duration of attacks 5–20 min Few
Response to indomethacin
Complete Co
Doses (mg/day) 150 75
Days taken to show complete response 4 2
Side effects of indomethacin pain abd, –
* = maximum tried dose.
abd: abdomen; conj: conjunctival injection; front: frontal; lacri: lacrimation; nau: naus
photophobia; rhin: rhinorrhea; tem: temporal; throb: throbbing; vom: vomiting.patients. Most patients (7 out of 8 patients) had intermit-
tent interictal pain. The diagnosis of hemicrania continua
(HC) was not considered in these patients because of the
mild and intermittent interictal pain. The frequency and
duration of the attacks were in accordance with the diag-
nostic criteria for PH. Moreover, these all patients denied
the presence of interictal pain during early periods of ill-
ness. In the subgroup analyses, we compared patients hav-
ing interictal pain to the patients not having such
background headache. There were statistically significant
differences in two parameters (Table 3). The patients hav-
ing interictal pain have a more chronic course (69.0 vs
10.7 months, p = 0.0006). The indomethacin dose require-
ment was also higher in patients with interictal pain
(187.5 vs 113.9, p = 0.0018). There were no other differ-
ences between the groups (data not shown).
The usual duration of the attacks was between 2–30
minutes (in accordance to the ICHD-II criteria for PH)
(Table 4). However, the duration of attacks varied be-
tween a few seconds to 3 hours. The longest attack dur-
ation was more than 30 min in four patients (24%). Two
patients reported longest headache duration of 3 hours.
The possibility of cluster headache (CH) was less likely
in these patients as the overall duration of attacks (and




ronic Chronic Chronic Chronic
t Left Right Right
, tem, front Orb, tem Orb, tem, front Orb, tem,
ere non throb Severe throb Severe nonthrob Severe throb,
– – –
lacri, conj conj, rhin Conj, lacri,
u, – nau, phot, phon –
yes yes yes
– yes yes
15 0–5 1–4 5–15
sec- 20 min 5–20 min 5–30 min 5–20 min
mplete Complete Complete Incomplete
150 75 225*
4 3 –
Nau, vom – –
ea; nonthrob: nonthrobbing; orb: orbital; phon: phonophobia; phot:
Table 3 A comparison between patients with interictal








69.0 ± 40.0 10.7 ± 6.2 0.0006*
Indomethacin dose
(mg/day)
187.5 ± 40.1 113.9 ± 39.7 0.0018*
* p = <0.005: significant.
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dian periodicity. Absence of circadian rhythmicity and
periodicity (clustering) also favors the diagnosis of PH.
The ICHD-II criteria for the frequency of attacks in PH
are > 5 attacks per day for more than half of the time. All
included patients fulfilled this criterion. The maximum at-
tack frequencies in these 17 patients were 10–20 per day.
The minimum attack frequencies were 0–5 per day. Three
patients never had frequency of more than 5 attacks per
day. We described it separately as atypical PH (Table 2).
Nocturnal attacks were noted in 6 patients (35%). How-
ever, none of the patients reported nocturnal preponder-
ance or periodicity. Agitation or a sense of restlessness
was present in 13 patients (76%).
There was at least one migrainous feature of nausea,
or vomiting, photophobia, or phonophobia in 9 (53%)
patients.Table 5 Details of indomethacin used in patients with PH
Parameters PH (n-17)
Indomethacin dose
Mean ± SD ( mg\daily) 149 ± 54
≤ 75 mg\daily 3 (18)
> 75–150 mg/daily 10 (59)Periodicity and chronicity of PH
PH is classified as episodic paroxysmal hemicrania (EPH)
or chronic paroxysmal hemicrania (CPH) depending on
the presence of a remission period. Fifteen (88%) patients
had a chronic course. Fourteen of these patients had a
chronic course since onset (primary chronic CPH). The
headache began as EPH and transitioned to CPH in one
patient. The course of headache was like primary EPH in
two patients (12%).Table 4 Durations and frequency of attacks in PH
Parameters PH (n-17)
Durations of attacks
< 2 minutes 7 (41%)
2–30 minutes 17 (100%)
> 30 minutes 4 (24%)
Attacks frequency
>5/day for more than half of the time 17 (100%)
maximum attack frequency 10–20/day
minimum attack frequency 0–5/day
Nocturnal attacks 6 (35%)Response to indomethacin
A response to indometacin is considered as a sine qua non
in PH [1]. All patients responded to indomethacin. The
details of response to indomethacin are summarized in
Table 5. The mean effective daily dose of indomethacin
was 149 mg (range 50–225). As noted earlier, the indo-
methacin dose requirement was higher in patients with
interictal pain (187.5 vs 113.9, p = 0.0018). Fifteen patients
(88%) showed a complete response in a week (7 days). An-
other two patients (12%) took 1–2 weeks to show the
complete response to indomethacin. None of the patient
was subjected to “indo” test because of the non availability
of injectable indomethacin. Eight patients (47%) were
subjected to tapering off indomethacin. Only one patient
was successfully weaned off the drug. The patient did not
have recurrence of headaches in the next 6 months follow
up. There was no prior history of episodic pattern of PH
in this patient. Sudden withdrawal of indomethacin (be-
cause of the side effects of indomethacin or poor compli-
ance) was noted in 7 patients. Withdrawal of the drugs led
to a recurrence of headaches within 2–10 days.
Prospectively, we gave topiramate to 4 patients.
Topiramate was started because of the development of
side effects of indomethacin. Two patients showed a
complete response to the drug. Both the patients showed
complete response at the dosage of 100 mg bid.
None of the patients received a correct diagnosis before
reporting to us. Migraine (65%), cluster headache (59%)
and atypical facial (35%) pain were the most common
diagnoses. Various drugs have been used in the past in
these patients. The details were not available for each drug> 150–225 mg/daily 4 (23)
> 225 mg/daily 0 (0)
Time interval between indomethacin administration and complete
response
< 24 hrs 4 (23)
1–7 days 11 (65)
> 7 days 2 (12)
Side effects by indomethacin
Nausea/vomiting 9 (53)
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(> 50%) to either verapamil (3 patients) or lithium (2 pa-
tients). These all four patients (diagnosed previously as
CH) showed a complete response to indomethacin. Fre-
quencies, duration, pattern (without periodicity) of the at-
tacks were also more compatible with the diagnosis of PH.
Atypical paroxysmal hemicrania
We identified 5 patients in whom one of the features of
the diagnostic criteria for PH was missing. We identified
2 patients with PH-like headaches without any cranial
autonomic features. These 2 patients look like CPH,
with respect to the frequency and duration of attacks
and response to indomethacin. They fulfilled the ICHD-
II diagnostic criteria for CPH, with the exception of
autonomic symptoms. There was no better alternative
diagnosis for these patients. We considered these pa-
tients as atypical or probable PH. In parallel, we identi-
fied 2 additional patients with PH-like headaches except
the absence of the required number of the attacks per
day to fulfill the ICHD-II criteria for PH. The ICHD-II
criteria for the number of attacks per day are more than
five attacks for more than half of the time. The attack
frequency in these two patients was ≤ 5 / day. These 2
patients resemble CPH in respect to other features of
PH according to the ICHD-II criteria. There was no bet-
ter alternative diagnosis for these patients. We consid-
ered even these patients as atypical or probable PH. One
patient fulfilled all the features of PH except the complete
response to indomethacin. This patient showed marked
improvement in frequency (5–15 /day to 0–5/day). The
intensity and duration of attacks also reduced markedly.
The patient had never felt such type of improvement with
any drug in the past.
Discussion
Prevalence and other epidemiological feature
PH is considered as a rare primary headache disorder. It
is suggested that cases of PH are probably overlooked or
underreported [4]. PH was first described in 1974 [5]. In
the first 15 yrs (up to 1989), a total 84 cases of PH were
reported in the literature [6]. However, in the next 10
years (up to 1998), only 27 cases were reported [7]. In
2002, Boes and Dodick reported 74 patients with CPH
(Goadsby and Lipton’s criteria) [2]. Isolated PH cases are
no longer reported now days [4]. However, the literature
is scarce even for larger case series. During the last 12
years, only one large case series (31 patients) has been
reported [8]. These suggest that cases of PH are
underreported or overlooked.
In the early years, the prevalence of PH was estimated in
relation to the prevalence of CH, and it was 0.9 to 3% [6].
This estimation was done by Antonaci and Sjasstad in
1989 (within the first 15 yrs of the discovery of the firstcase of PH) [6]. The authors predicted “this ratio may
change considerably in the foreseeable future”. After 1989,
we noted at least two studies where PH was compared to
CH. In 2002, Faud and Jones [9] reported 11 patients with
PH. In parallel, they reported 30 patients with CH over
the same period. The ratio of PH to CH was 30%. In the
same way, this ratio was 15% in Zidverc-Trajkovic et al.
study [10]. According to these two studies, the prevalence
of PH (with respect to CH) may be more than 15% of CH.
This indicates that PH is probably more common than it
was anticipated earlier. Seidel et al. [11] reported 63 con-
secutive patients with unilateral headache not resembling
migraine or CH. Only twenty-four patients received a
diagnosis of primary headache disorders. Six of them had
PH. Blankenburg [12] reported 8 children with PH among
628 children (1.3%) with chronic daily headache and sug-
gested that PH is under diagnosed even in children. A
possibility of misdiagnosis also exists. Initially, PH was
considered as a disease of the female (2.3 to 7: 1) [4].
However, in Cittadini case series (31 patients), female pre-
ponderance was not obvious. The authors suggested that
it may be because of mis-diagnosis of males with PH as
cluster headache, as it is the more common with a distinct
male preponderance. Our all patients were never diag-
nosed previously before reporting to us. This suggests that
a possibility of mis-diagnosis or unawareness to PH may
be very high.
Taken together, PH is probably an under diagnosed and
underreported primary headache disorder. We observed
17 patients with PH (and 5 probable PH) over 6 years dur-
ation. Our case series is probably the third largest case
series in the literature.
The mean age of onset (38 yrs) was comparable to
other studies. In Cittadini et al. series [8], it was 37 yrs
and in a review of 84 patients, mean age was 34 yrs [6].
PH is classically considered as a disease with female pre-
ponderance. However, in Cittadini et al. series [8], male
outnumbered female (17 vs 14). In our series male: fe-
male was 1:1.1 (8 male vs 9 female). These two observa-
tions suggest that both male and female may be equally
affected.Duration and frequency of attacks
Seventeen patients fulfilled the criteria for PH. The
closet differential diagnosis of PH is CH [4]. Clinical
characteristics for both PH and CH is similar. PH is usu-
ally distinguished from other TACs by the duration and
frequency of attacks and by a response to indomethacin
in patients with PH [1,4]. However, as there is overlap in
the diagnostic criteria for PH and CH, a possibility of
misdiagnosis always exist in patients with PH and vice-
versa [8,13]. Presence of indomethacin responsive CH
may further complicate the issue [13].
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quency of attacks were more compatible with the diag-
nosis of PH. All patients had headache duration between
5–30 minutes (as defined in the ICHD-II criteria for
PH). Only four patients (24%) had a few headache at-
tacks of more than 30 minutes. In Cittadini et al. series
[8], 55% patients had the longest attack duration of more
than 30 min. In Boes and Dodick case series [2], the
maximum attack duration was more than 60 minutes in
41% patients. A patient may have a few attacks of many
hours. This indicates that a few attacks in a patient may
be more than of 30 minutes (an upper limit defined in
ICHD-II criteria for PH). This may create diagnostic
confusion, and a misdiagnosis as CH or migraine exists
if patient or physician focuses mainly on maximum at-
tack duration. Therefore, mean or average duration of
the attacks should be considered in making the diagnosis
of PH and other TACs.
In the same way, the frequency of attacks is also an
important point in making the diagnosis of PH. More
than 5 attacks per day for more than half of the time is
essential to make the diagnosis of PH. All 17 patients
(typical PH) fulfilled this criterion. The maximum attack
frequency was ≥ 10 / day in all 17 patients. However, we
observed 2 more patients who never had 5 or more at-
tacks in a day. Other clinical features, including response
to indomethacin were according to the ICHD-II criteria
for PH. We considered these two patients as atypical
PH. Although ICHD-II acknowledges the presence of
lower frequency in patients with PH, ≥ 5 / day for more
than half of the time is must to fulfill the criteria. In re-
view of the literature, we noted a number of patients
with the maximum attack frequency of < 5 / day. The
maximum attack frequency was between 2 and 5 in 37%
patients in Boes and Dodick case series [2]. In Cittadini case
series [8], at least three patients had a maximum attack fre-
quency of less than five in a day. In Zidverc-Trajkovic
et al. observations [10], two patients (out of eight
patients) had attack duration shorter than proposed by
ICHD-II criteria. These observations suggest that a few
patients may never have attack frequency of more than
5 in a day.
Cranial autonomic features
Patients with PH are required to have at least one of the
cranial autonomic features according to ICHD-II cri-
teria. Our three patients (16%) never had autonomic fea-
tures. Two (4%) patients in Boes and Dodick case series
[2] had no autonomic features. One patient in Cittadini
case series had not any classical autonomic features and
reported only a sense of ear fullness during the attacks.
Maggioni [3] reported a case of episodic PH with no cra-
nial autonomic feature and suggested a possibility of a
subgroup of PH. Similar observations have also beennoted in patients with CH and HC. Three to seven per-
cent patients with CH may never have cranial autonomic
features during CH attacks [14]. Various case series sug-
gest that a large number of patients with HC may never
have autonomic feature during the exacerbation of at-
tacks [15]. Feeling of sand or itching in eye is classically
described as an autonomic feature in patients with HC
[15]. Our 8 patients (47%) mentioned the feeling of sand
or itching in eye during the headache episodes. These
observations need to be confirmed prospectively in other
case series.
It is suggested that the presence of autonomic features
is related to the intensity of the headaches [14]. Auto-
nomic features are less likely to occur in patients with
moderate to severe rather than excruciating attacks of
pain. As the intensity of pain attacks in PH is much less
than attacks of CH, absence of autonomic feature is pos-
sible even in patients with PH. ICHD-II acknowledges
the diagnosis of CH in the absence of cranial autonomic
features ( if patient has restlessness) [1]. The similar sug-
gestion has been given even for making the diagnosis of
HC (i.e. HC should be diagnosed even in the absence of
cranial autonomic feature) [15]. Therefore, we suggest
that ICHD-II should acknowledge the diagnosis of PH
even in the absence of autonomic symptoms.
Restlessness/agitation
Restlessness or agitation is classically described in pa-
tients with CH and it is one of the components of the
ICHD-II diagnostic criteria for CH. It provides an alter-
native to make the diagnosis of CH even in the absence
of autonomic feature. A few authors suggest that rest-
lessness or agitation should also be included in the diag-
nostic criteria for HC [15,16]. Review of the literature
suggests that restlessness or agitation may be noted in
50-90% of patients with PH. Our 76% reported restless-
ness or agitation. We suggest that like CH, restlessness /
agitation should be included in the diagnostic criteria for
PH, as it would provide alternative to make the diagnosis
of PH in the absence of autonomic feature.
Lack of complete indomethacin response
A response to indometacin is considered as a sine qua
non in PH. Our one patient had an incomplete response
to indomethacin. In Boes and Dodick case series [2],
25% (10/40) patients did not exhibit responses to indo-
methacin. A few other patients (6 patients) had only a
partial response to indomethacin. In the other two pa-
tients, a complete response to indomethacin was not
sustained.
HC is another indomethacin responsive primary head-
ache disorder. However, recent observations indicate that
the indomethacin resistant HC is a distinct possibility
[15,17,18]. In an earlier review, we suggested a possibility
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as it is difficult to classify such patients according to the
present ICHD-II classification [18]. The same possibility
may exist for PH unresponsive to indomethacin and it
may be the reason for underreporting of PH in the litera-
ture. In a review, we noted that CH may be wrongly diag-
nosed as PH if patients with CH show a response to
indomethacin [13]. Therefore, a possibility exists that
PH unresponsive to indomethacin (especially borderline
cases) can be diagnosed as CH. As the prevalence of CH
is very high than PH, a possibility of misdiagnosis of PH
as CH is more likely (than CH diagnosed as PH). Pa-
tients with PH also show response to lithium, verapamil,
and topiramate. Therefore, a patient will not receive the
diagnosis of PH, if a patient shows a response to an-
other drug before a trial to indomethacin. Our five pa-
tients (29%) showed a partial response to lithium and
verapamil (before a trial of indomethacin), and were
labeled as CH. Prospectively our 2 patients showed a
response to topiramate.
Interictal pain
Eight of 17 patients (47%) reported interictal pain. Seven
of these (88%) had intermittent pain. This interparoxysmal
pain was usually mild and was mainly described as dis-
comfort in that area. The presence of interictal pain may
create diagnostic confusion with HC [15]. However, “mild”
and “intermittent” nature of interparoxysmal pain favors
the diagnosis of PH. Moreover, frequency and duration of
attacks were more compatible with the diagnosis of PH.
Frequency and duration of the exacerbations in patients
with HC are highly variable and duration of attacks fre-
quently crosses the upper defined levels of PH (and CH)
[15]. The exacerbations in a patient with HC vary be-
tween a few minutes to many hours (may be upto days)
[15]. One patient reported continuous inteictal pain.
The interictal pain was mild, and periodic exacerbations
matched with the frequency and duration described for
PH. Moreover, the patient did not have interictal pain
during the early years of the disease.
We compared patients with interictal pain to patients
with no such pain. The mean duration of illness was sig-
nificantly higher in patients with interictal pain (69.0 vs
10.7 months, p = 0.0006). In the same way, patients with
interictal pain required a high dose of indomethacin
(188 vs 114 mg, p = 0.0018). These observations indicate
that patients with longer duration of history are more
likely to have interictal pain and these patients may re-
quire higher doses of indomethacin. Such type of obser-
vations was also noted in patients with CH [19]. In
Marmura et al’s case series [19], patients with a long his-
tory of disease were more likely to have interictal pain.
The patients with a long history of disease and interictal
pain were more refractory to the therapy. Variousmechanisms have been suggested for these observations.
It is said that any longstanding chronic pain may lead to
cortical changes in the brain and it may be responsible
for the interictal pain and refractoriness to therapy
[19-21]. As these patients may require higher doses of
indomethacin, an early diagnosis is very important.
Taken together, our case series and review of the lit-
erature suggest that a subgroup of patients may not ful-
fill the all the features of ICHD-II diagnostic criteria of
PH and a possibility of a subgroup of PH exist. There-
fore, we suggest the inclusion of a more accommodating
alternative diagnostic criteria or probable PH in the ap-
pendix section.
There are marked overlap in clinical features and
therapeutic responses among TACs. Clinical features
and therapeutic responses in patients with HC also over-
lap with TACs. Most pathophysiological studies on TACs
have been done in CH. The literature is relatively sparse
on PH, SUNCT, and HC. However, it is also suggested
that all three TACs and HC have common pathophysi-
ology [22]. In the absence of clear cut biological marker,
it will be difficult to differentiate borderline or atypical
cases of TACs and HC. In Seidel et al. [11] case series of
63 consecutive patients with unilateral headache not re-
sembling migraine or CH, only twenty-four patients
(38%) received a diagnosis of primary headache disor-
ders. Headaches could not be classified according to
present ICHD-II criteria in 49% patients. This suggests
that there is need of refinement of diagnostic criteria of
PH and other unilateral headache disorders.
Migraine is the best studied primary headache disorder
with well defined pathophysiology. In spite of these,
ICHD-II has provided an alternative diagnostic criterion
in the appendix section. In the same way, there is need
of alternative diagnostic criteria of various other primary
headache disorders, including PH. Therefore, till we get
biological marker of PH or other TACs, it will be better
to have more accommodating type of criteria in the ap-
pendix section so that we can refine rare primary head-
ache disorders in the future.
Limitations of our observations
This is a retrospective study and a possibility of unrecog-
nized selection bias and recall bias exists. Although we
included only those patients who had normal neuroimag-
ing, we cannot rule out secondary headaches, as full evalu-
ation for secondary headache was not performed on each
patient. In addition, we did not have the facilities to do
‘indotest’. Our observation did not have large enough num-
bers to reveal true differences between the typical PH
(ICHD-II fulfilled) and atypical PH. Despite these limita-
tions, our observations and review of the literature suggests
that a few patients may not fulfill all the ICHD-II criteria
for PH and there is need for refinement of the criteria.
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Present diagnostic criteria for PH are too restrictive and a
subset of patients may not have all the defined features of
PH. There is a need for refinement of the existing diagnos-
tic criteria.
Consent
Written informed consent was taken from the patients
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